Literature DB >> 8404106

Resting energy expenditure. Evolution during antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

H Naon1, S Hack, M T Shelton, R C Gotthoffer, D Gozal.   

Abstract

STUDY
OBJECTIVES: To compare the changes in resting energy expenditure (REE) to concomitant changes in clinical status and pulmonary function in cystic fibrosis (CF) patients during treatment for acute pulmonary exacerbation. To determine if weight loss during exacerbation in CF is related to decreased calorie intake or increased energy needs.
DESIGN: Measurements of REE, pulmonary function tests, oxygen saturation, respiratory rate, maximal inspiratory pressure (MIP), white blood cell count, chest x-ray films and attribution of clinical score (ACS) on admission, mid-hospitalization, and discharge. Anthropometric measurements on admission, assessment of dietary intake and nitrogen balance upon admission and prior to discharge.
SUBJECTS: Thirteen CF patients admitted for treatment of acute pulmonary exacerbation with a mean age of 11.0 +/- 7.9 (SD) years.
RESULTS: From admission to discharge, REE decreased from 44.5 +/- 9.0 to 33.8 +/- 8.5 kilocalorie (kcal)/kg/d (p < 0.003). Similarly, the ACS improved from 7.5 +/- 2.0 to 4.0 +/- 2.2 (p < 0.0001); the absolute neutrophil count decreased from 10,685 +/- 6,226/microliters to 6,363 +/- 168/microliters (p < 0.005); respiratory rate decreased from 32.6 +/- 6.2 to 25.0 +/- 3.7 breaths per minute (p < 0.01); and MIP increased from 77.5 +/- 20.0 to 90.0 +/- 20.4 cm H2O (p < 0.01). In parallel, less significant improvements occurred in pulmonary function tests, oxygen saturation and chest x-ray film scores. Calorie intake was 1,893 +/- 635 and 2,054 +/- 707 kcal/d on admission and discharge, respectively (p = NS); during hospitalization, weight increased from 23.6 +/- 10.1 to 25.7 +/- 10.1 kg (p < 0.005). While carbohydrate and fat content of the diet remained essentially unchanged, a significant increase in protein intake (3.15 +/- 0.92 to 3.5 +/- 0.81 g/kg/d [p < 0.05]) and in nitrogen balance (1.8 +/- 2.5 to 5.6 +/- 2.9 g of nitrogen per day [p < 0.05]) were observed.
CONCLUSIONS: In acute CF, pulmonary exacerbation, changes in REE parallel those of clinical improvements and are more sensitive than pulmonary function tests and chest x-ray films as an objective clinical correlate. Increased metabolic requirements but not decreased dietary intake are the cause of weight loss in CF patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8404106     DOI: 10.1378/chest.103.6.1819

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Non-invasive ventilation assists chest physiotherapy in adults with acute exacerbations of cystic fibrosis.

Authors:  A E Holland; L Denehy; G Ntoumenopoulos; M T Naughton; J W Wilson
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

2.  Nutrition and survival in cystic fibrosis.

Authors:  J S Elborn; S C Bell
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

3.  The Cystic Fibrosis Symptom Progression Survey (CF-SPS) in Arabic: A Tool for Monitoring Patient's Symptoms.

Authors:  Catherine Norrish; Mark Norrish; Uwe Fass; Majid Al-Salmani; Ganji Shiva Lingam; Fiona Clark; Hebal Kallesh
Journal:  Oman Med J       Date:  2015-01

4.  Nutritional impact of antipseudomonas intravenous antibiotic courses in cystic fibrosis.

Authors:  P Vic; S Ategbo; F Gottrand; V Launay; G A Loeuille; J C Elian; D Druon; J P Farriaux; D Turck
Journal:  Arch Dis Child       Date:  1997-05       Impact factor: 3.791

5.  Influence of gender and interleukin-10 deficiency on the inflammatory response during lung infection with Pseudomonas aeruginosa in mice.

Authors:  Claudine Guilbault; Peter Stotland; Claude Lachance; Mifong Tam; Anna Keller; Luann Thompson-Snipes; Elizabeth Cowley; Thomas A Hamilton; David H Eidelman; Mary M Stevenson; Danuta Radzioch
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

6.  Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease.

Authors:  Silke Besier; Christina Smaczny; Christian von Mallinckrodt; Andreas Krahl; Hanns Ackermann; Volker Brade; Thomas A Wichelhaus
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

Review 7.  Management of cystic fibrosis before and after lung transplantation.

Authors:  J J Egan; A A Woodcock; A K Webb
Journal:  J R Soc Med       Date:  1997       Impact factor: 18.000

8.  Resting energy expenditure and nutritional state of patients with increased oxygen cost of breathing due to emphysema, scoliosis and thoracoplasty.

Authors:  M K Sridhar; R Carter; M E Lean; S W Banham
Journal:  Thorax       Date:  1994-08       Impact factor: 9.139

9.  Practical guidelines: lung transplantation in patients with cystic fibrosis.

Authors:  T O Hirche; C Knoop; H Hebestreit; D Shimmin; A Solé; J S Elborn; H Ellemunter; P Aurora; M Hogardt; T O F Wagner
Journal:  Pulm Med       Date:  2014-03-30

Review 10.  Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis.

Authors:  Adam J Causer; Janis K Shute; Michael H Cummings; Anthony I Shepherd; Mathieu Gruet; Joseph T Costello; Stephen Bailey; Martin Lindley; Clare Pearson; Gary Connett; Mark I Allenby; Mary P Carroll; Thomas Daniels; Zoe L Saynor
Journal:  Redox Biol       Date:  2020-01-23       Impact factor: 11.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.